Overdiagnosis of invasive breast cancer due to mammography screening: Results from the norwegian screening program

Annals of Internal Medicine

Volumn 156, Issue 7, 2012, Pages 491-499

  Kalager, Mette ^a   Adami, Hans Olov ^b   Bretthauer, Michael ^c   Tamimi, Rulla M ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MENOPAUSE; NORWAY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 84859357955     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-156-7-201204030-00005     Document Type: Article

References (43)

1. Vainio H, Bianchini F. IARC Handbook of Cancer Prevention. Lyon, France: IARC Pr; 2001.
2. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ. 2009; 339:b2587. [PMID: 19589821]
3. Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: Prospective cohort study. BMJ. 2004;328:921-924. [PMID: 15013948]
4. Jørgensen KJ, Zahl PH, Gøtzsche PC. Overdiagnosis in organised mammography screening in Denmark. A comparative study. BMC Womens Health. 2009;9:36. [PMID: 20028513]
5. Zahl PH, Maehlen J, Welch HG. The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med. 2008;168: 2311-2316. [PMID: 19029493]
6. Morrell S, Barratt A, Irwig L, Howard K, Biesheuvel C, Armstrong B. Estimates of overdiagnosis of invasive breast cancer associated with screening mammography. Cancer Causes Control. 2010;21:275-282. [PMID: 19894130]
7. Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L. Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol. 2007;8:1129-1138. [PMID: 18054882]
8. Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of overdiagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. BMJ. 2006;332:689-692. [PMID: 16517548]
9. Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Bjorneld L, et al. Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res. 2005;7:258-265. [PMID: 16457701]
10. de Koning HJ, Draisma G, Fracheboud J, de Bruijn A. Overdiagnosis and overtreatment of breast cancer: microsimulation modelling estimates based on observed screen and clinical data. Breast Cancer Res. 2006;8:202. [PMID: 16524452]
11. Paci E, Miccinesi G, Puliti D, Baldazzi P, De Lisi V, Falcini F, et al. Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy. Breast Cancer Res. 2006;8:R68. [PMID: 17147789]
12. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2009:CD001877. [PMID: 19821284]
13. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med. 2010;363:1203-1210. [PMID: 20860502]
14. Larsen IK, Småstuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45:1218-1231. [PMID: 19091545]
15. Tingulstad S, Halvorsen T, Norstein J, Hagen B, Skjeldestad FE. Completeness and accuracy of registration of ovarian cancer in the cancer registry of Norway. Int J Cancer. 2002;98:907-911. [PMID: 11948471]
16. Kalager M, Kåresen R, Wist E. Survival after breast cancer-differences between Norwegian counties. Tidsskr Nor Laegeforen. 2009;129:2595-2600. [PMID: 20029554]
17. Perry N, Broeders M, de Wolf C. European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis. 2nd ed. Luxembourg, Belgium; 1996.
18. Statistics Norway. StatBank Norway. Accessed at http://statbank.ssb.no/statistikkbanken/Default_FR.asp?PXSid=0&nvl=true&PLanguage=0&tilside=selecttable/MenuSelS.asp&SubjectCode=02 on 23 March 2009.
19. MacMahon B, Trichopoulos D. Epidemiology: Principles and Methods 2nd ed. Boston: Little, Brown; 1996.
20. Duffy SW, Lynge E, Jonsson H, Ayyaz S, Olsen AH. Complexities in the estimation of overdiagnosis in breast cancer screening. Br J Cancer. 2008;99: 1176-1178. [PMID: 18766185]
21. Gøtzsche PC, Jørgensen KJ, Maehlen J, Zahl PH. Estimation of lead time and overdiagnosis in breast cancer screening [Letter]. Br J Cancer. 2009;100:219. [PMID: 19127274]
22. Boer R, Warmerdam P, de Koning H, van Oortmarssen G. Extra incidence caused by mammographic screening [Letter]. Lancet. 1994;343:979. [PMID: 7909035]
23. Weedon-Fekjaer H, Lindqvist BH, Vatten LJ, Aalen OO, Tretli S. Estimating mean sojourn time and screening sensitivity using questionnaire data on time since previous screening. J Med Screen. 2008;15:83-90. [PMID: 18573776]
24. Shen Y, Zelen M. Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution. Biostatistics. 2005;6:604-614. [PMID: 15860542]
25. Zahl PH, Jørgensen KJ, Maehlen J, Gøtzsche PC. Biases in estimates of overdetection due to mammography screening [Letter]. Lancet Oncol. 2008;9: 199-201. [PMID: 18308246]
26. Welch HG, Woloshin S, Schwartz LM. The sea of uncertainty surrounding ductal carcinoma in situ-the price of screening mammography [Editorial]. J Natl Cancer Inst. 2008;100:228-229. [PMID: 18270336]
27. Sørum R, Hofvind S, Skaane P, Haldorsen T. Trends in incidence of ductal carcinoma in situ: the effect of a population-based screening programme. Breast. 2010;19:499-505. [PMID: 21071225]
28. Jensen A, Olsen AH, von Euler-Chelpin M, Helle Njor S, Vejborg I, Lynge E. Do nonattenders in mammography screening programmes seek mammogra-phy elsewhere? Int J Cancer. 2005;113:464-470. [PMID: 15455383]
29. Drug Consumption in Norway 2006-2010. Accessed at www.legemiddelfor-bruk.no on 28 March 2011.
30. Waaseth M, Bakken K, Lund E. Patterns of hormone therapy use in the Norwegian Women and Cancer study (NOWAC) 1996-2005. Maturitas. 2009; 63:220-226. [PMID: 19394168]
31. Bakken K, Alsaker E, Eggen AE, Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer. 2004;112:130-134. [PMID: 15305384]
32. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419-427. [PMID: 12927427]
33. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333. [PMID: 12117397]
34. Magnusson C, Baron JA, Correia N, Bergström R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer. 1999;81:339-344. [PMID: 10209946]
35. Weedon-Fekjaer H, Sørum R, Brenn MK. Hormone therapy use may explain recent results regarding tumor regression [Letter]. Arch Intern Med. 2009; 169:996-997. [PMID: 19468094]
36. Welch HG, Schwartz LM, Woloshin S. Ramifications of screening for breast cancer: 1 in 4 cancers detected by mammography are pseudocancers [Letter]. BMJ. 2006;332:727. [PMID: 16565136]
37. Welch HG, Black WC. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med. 1997;127:1023-1028. [PMID: 9412284]
38. Jatoi I, Anderson WF. Cancer screening. Curr Probl Surg. 2005;42:620-682. [PMID: 16154400]
39. Autier P, Héry C, Haukka J, Boniol M, Byrnes G. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J Clin Oncol. 2009;27:5919-5923. [PMID: 19884547]
40. Autier P, Boniol M, Middleton R, Doré JF, Héry C, Zheng T, et al. Advanced breast cancer incidence following population-based mammographic screening. Ann Oncol. 2011;22:1726-1735. [PMID: 21252058]
41. Widmark A, Olsen JB. Mammografi virksomhet I Norge. Tekniske resul-tater. StrålevernRapporten. 1995:5. Østerås, Norway: Statens Sålevern; 1995.
42. Rostgaard K, Vaeth M, Rootzén H, Lynge E. Why did the breast cancer lymph node status distribution improve in Denmark in the pre-mammography screening period of 1978-1994? Acta Oncol. 2010;49:313-321. [PMID: 20397766]
43. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Breast screening: the facts- or maybe not. BMJ. 2009;338:b86. [PMID: 19174442]